Ligand Pharmaceuticals Acquires Portfolio of Milestone and Royalty Payments From Selexis SA

Represented Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) in its acquisition of a portfolio of milestone and royalty payments of more than 15 biologic development programs from Selexis SA for $4 million in cash. Ligand also previously acquired a separate portfolio of more than 15 programs from Selexis in 2013.

Selexis SA is a privately-held global life science company that focuses on discovering therapeutic protein drugs. Ligand is a biopharmaceutical company that focuses on developing and or acquiring technologies that help pharmaceutical companies in discovering and creating medicines. Read the press release.

San Diego-based Hayden Trubitt represented Ligand Pharmaceuticals in this transaction.